Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 3Myeloid 3Lymphoid 3Plasma cell 1

Conditions

Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Multiple Myeloma 1Leukemia, Prolymphocytic, T-Cell 1Leukemia, Plasma Cell 1Leukemia, Myelomonocytic, Chronic 1Leukemia 1

Interventions

Cyclophosphamide 89fludarabine phosphate 77Mycophenolic Acid 53Tacrolimus 52Peripheral Blood Stem Cell Transplantation 50Busulfan 44Whole-Body Irradiation 43Antilymphocyte Serum 41fludarabine 37Cyclosporine 36Filgrastim 32Melphalan 27Methotrexate 26Radiotherapy 23Cord Blood Stem Cell Transplantation 19Methylprednisolone 18Granulocyte Colony-Stimulating Factor 16Sirolimus 14Etoposide 13Alemtuzumab 12thymoglobulin 11sargramostim 11Stem Cell Transplantation 11Rituximab 11Thiotepa 9Azacitidine 8Cytarabine 7Psychiatric Rehabilitation 6Prednisone 6Flow Cytometry 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Myelodysplastic Syndromes × itacitinib × Plasma cell × Clear all
NCT05823571 2025-09-18

Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older Patients

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 1 Active not recruiting
32 enrolled
LymphoidMyeloidOther hematologic neoplasmPlasma cell

Leukemia, Leukemia, Plasma Cell, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Prolymphocytic, T-Cell, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡